EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatme...
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
About this item
Full title
Author / Creator
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
EZH2
is mutated in nearly 25% of follicular lymphoma (FL) cases. Little is known about how
EZH2
affects patients’ response to therapy. In this context, the aim of this study was to retrospectively analyze the frequency of mutations in
EZH2
at diagnosis in tissue and ctDNA in patients with FL and to assess the patients’ outcomes after...
Alternative Titles
Full title
EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a73ed3e09e1d48fda50b721b1ee08a09
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a73ed3e09e1d48fda50b721b1ee08a09
Other Identifiers
ISSN
1471-2407
E-ISSN
1471-2407
DOI
10.1186/s12885-022-10070-z
